The tumour border was more often infiltrative in the TP53 cohort, 36 of 36 (100.0%), and amongst HER2 positive cases, 52 of 55 (94.5%), compared to the BRCA1, BRCA2 and YBC cases – 58 of 138 (42.0%), 93 of 157 (59.2%), 122 of 217 (56.2%) respectively. This evidence concerns the gene ERBB2 and neoplasm.